User login
Key clinical point: In real-life settings, patients with chronic myeloid leukemia (CML) in accelerated or chronic phase treated with new-generation tyrosine kinase inhibitor (NG-TKI) therapy in first line were more likely to achieve major molecular response (MMR) vs. those treated with imatinib.
Major finding: Patients receiving NG-TKI vs. imatinib were more likely to achieve MMR (77% vs. 61%; hazard ratio 1.88; 95% CI 1.35-2.61).
Study details: Findings are from a retrospective, population-based study including 507 adult patients with chronic or accelerated phase CML treated first with either imatinib (n = 388) or NG-TKI (nilotinib, n = 90; dasatinib, n = 24; bosutinib, n = 3; ponatinib, n = 2).
Disclosures: This study was funded by Force Hémato with the support of Novartis and supported by La Ligue Contre le Cancer. P Cony-Makhoul reported grants from Force Hémato. Other authors declared no conflict of interests.
Source: Canet J et al. Cancer Med 2021 Sep 22. doi: 10.1002/cam4.4186.
Key clinical point: In real-life settings, patients with chronic myeloid leukemia (CML) in accelerated or chronic phase treated with new-generation tyrosine kinase inhibitor (NG-TKI) therapy in first line were more likely to achieve major molecular response (MMR) vs. those treated with imatinib.
Major finding: Patients receiving NG-TKI vs. imatinib were more likely to achieve MMR (77% vs. 61%; hazard ratio 1.88; 95% CI 1.35-2.61).
Study details: Findings are from a retrospective, population-based study including 507 adult patients with chronic or accelerated phase CML treated first with either imatinib (n = 388) or NG-TKI (nilotinib, n = 90; dasatinib, n = 24; bosutinib, n = 3; ponatinib, n = 2).
Disclosures: This study was funded by Force Hémato with the support of Novartis and supported by La Ligue Contre le Cancer. P Cony-Makhoul reported grants from Force Hémato. Other authors declared no conflict of interests.
Source: Canet J et al. Cancer Med 2021 Sep 22. doi: 10.1002/cam4.4186.
Key clinical point: In real-life settings, patients with chronic myeloid leukemia (CML) in accelerated or chronic phase treated with new-generation tyrosine kinase inhibitor (NG-TKI) therapy in first line were more likely to achieve major molecular response (MMR) vs. those treated with imatinib.
Major finding: Patients receiving NG-TKI vs. imatinib were more likely to achieve MMR (77% vs. 61%; hazard ratio 1.88; 95% CI 1.35-2.61).
Study details: Findings are from a retrospective, population-based study including 507 adult patients with chronic or accelerated phase CML treated first with either imatinib (n = 388) or NG-TKI (nilotinib, n = 90; dasatinib, n = 24; bosutinib, n = 3; ponatinib, n = 2).
Disclosures: This study was funded by Force Hémato with the support of Novartis and supported by La Ligue Contre le Cancer. P Cony-Makhoul reported grants from Force Hémato. Other authors declared no conflict of interests.
Source: Canet J et al. Cancer Med 2021 Sep 22. doi: 10.1002/cam4.4186.